A-5789, titled “Prohibits denial of health benefits coverage for prescription drugs based on accelerated FDA approval,” would add a rule to New Jersey law supplementing P.L.1997, c.192. Its stated goal is to prevent health plans from excluding, restricting, or delaying drug coverage because the drug received FDA accelerated approval. The bill is introduced and is not law; if enacted, it would take effect 120 days later and apply to contracts entered into or renewed after that date.
No publicly available information gives a cost estimate.
Bills on related subjects, starting with New Jersey.
The bill would require the insurance commissioner to create one standard form for network providers seeking prescription drug coverage decisions, which payers must accept on paper or electronically.
Status
Introduced, Referred to Assembly Financial Institutions and Insurance Committee
Lawmakers would require health plans and Medicaid to cover 12-month refills of qualifying nonrefrigerated hormone therapy; Medicaid members would pay no cost-sharing.
Status
Introduced, Referred to Assembly Financial Institutions and Insurance Committee
Insurers and state and school employee health plans would have to cover physician-deemed medically necessary sepsis care like other conditions for qualifying contracts made or renewed 180 days after enactment.
Status
Introduced, Referred to Assembly Financial Institutions and Insurance Committee
The bill would require health insurers and state employee health-benefit programs to let covered people send and receive plan messages electronically, including claims and enrollment.
Status
Introduced, Referred to Assembly Financial Institutions and Insurance Committee